Literature DB >> 33455827

What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk?

Deborah J Bowen1, Sukh Makhnoon2, Brian H Shirts3, Stephanie M Fullerton4, Eric Larson5, James D Ralston6, Kathleen Leppig7, David R Crosslin8, David Veenstra9, Gail P Jarvik10.   

Abstract

OBJECTIVE: We currently rely on probands to communicate genetic testing results and health risks within a family to stimulate preventive behaviors, such as cascade testing. Rates of guidelines-based cascade testing are low, possibly due to low frequency or non-urgent communication of risk among family members. Understanding what is being communicated and why may help improve interventions that increase communication and rates of cascade testing.
METHODS: Participants (n = 189) who were to receive both positive and negative colorectal cancer (CRC) sequencing results completed surveys on family communication, family functioning, impact of cancer in the family, and future communication of risk and were participants in eMERGE3. Questions were taken from existing surveys and administered electronically using email and a web driven tool.
RESULTS: Common family member targets of CRC risk communication, before results were received, were mothers and fathers, then sisters and grandchildren and finally, children and brothers. A communication impact score of 0.66 (sd = 0.83) indicated low-to-moderate communication impact. Age and education were significantly associated with frequency of familial communication, but not on the cancer-related impact of familial communication.
CONCLUSIONS: There is infrequent communication about cancer risk from probands to family members. PRACTICE IMPLICATIONS: These results demonstrate an opportunity to help families improve communication.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CRC risk; Familial communication

Mesh:

Year:  2021        PMID: 33455827      PMCID: PMC8005444          DOI: 10.1016/j.pec.2021.01.001

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  18 in total

1.  CONSORT revised--improving the reporting of randomized trials.

Authors:  D Rennie
Journal:  JAMA       Date:  2001-04-18       Impact factor: 56.272

2.  The role of the family in genetic testing: theoretical perspectives, current knowledge, and future directions.

Authors:  Susan K Peterson
Journal:  Health Educ Behav       Date:  2005-10

3.  Estimating the efficacy and efficiency of cascade genetic screening.

Authors:  M Krawczak; D N Cooper; J Schmidtke
Journal:  Am J Hum Genet       Date:  2001-06-26       Impact factor: 11.025

4.  Informing one's family about genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a retrospective exploratory study.

Authors:  Ilse Mesters; Marlein Ausems; Sophie Eichhorn; Hans Vasen
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Effects of a Web-based intervention on women's breast health behaviors.

Authors:  Deborah J Bowen; Robert Robbins; Nigel Bush; Hendrika Meischke; Abi Ludwig; Jean Wooldridge
Journal:  Transl Behav Med       Date:  2011-03       Impact factor: 3.046

6.  Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.

Authors:  Uri Ladabaum; Grace Wang; Jonathan Terdiman; Amie Blanco; Miriam Kuppermann; C Richard Boland; James Ford; Elena Elkin; Kathryn A Phillips
Journal:  Ann Intern Med       Date:  2011-07-19       Impact factor: 25.391

7.  Patient goals, motivations, and attitudes in a patient-driven variant reclassification study.

Authors:  Ginger J Tsai; Lauren Thomas Garrett; Sukh Makhnoon; Deborah J Bowen; Wylie Burke; Brian H Shirts
Journal:  J Genet Couns       Date:  2018-12-31       Impact factor: 2.537

8.  Genetic counseling and cascade genetic testing in Lynch syndrome.

Authors:  Heather Hampel
Journal:  Fam Cancer       Date:  2016-07       Impact factor: 2.375

9.  The KinFact intervention - a randomized controlled trial to increase family communication about cancer history.

Authors:  Joann N Bodurtha; Donna McClish; Maria Gyure; Rosalie Corona; Alexander H Krist; Vivian M Rodríguez; Alisa M Maibauer; Joseph Borzelleca; Deborah J Bowen; John M Quillin
Journal:  J Womens Health (Larchmt)       Date:  2014-10       Impact factor: 2.681

10.  Development and preliminary validation of the cancer family impact scale for colorectal cancer.

Authors:  Pamela S Sinicrope; Sally W Vernon; Pamela M Diamond; Christi A Patten; Steven H Kelder; Kari G Rabe; Gloria M Petersen
Journal:  Genet Test       Date:  2008-03
View more
  4 in total

Review 1.  A systematic review of theory-informed strategies used in interventions fostering family genetic risk communication.

Authors:  Jingsong Zhao; Yue Guan; Colleen M McBride
Journal:  Patient Educ Couns       Date:  2022-03-11

2.  Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant.

Authors:  Anne Brédart; Antoine De Pauw; Amélie Anota; Anja Tüchler; Julia Dick; Anita Müller; Jean-Luc Kop; Kerstin Rhiem; Rita Schmutzler; Peter Devilee; Dominique Stoppa-Lyonnet; Sylvie Dolbeault
Journal:  Breast       Date:  2021-08-23       Impact factor: 4.380

3.  The Communication Chain of Genetic Risk: Analyses of Narrative Data Exploring Proband-Provider and Proband-Family Communication in Hereditary Breast and Ovarian Cancer.

Authors:  Carla Pedrazzani; Monica Aceti; Reka Schweighoffer; Andrea Kaiser-Grolimund; Nicole Bürki; Pierre O Chappuis; Rossella Graffeo; Christian Monnerat; Olivia Pagani; Manuela Rabaglio; Maria C Katapodi; Maria Caiata-Zufferey
Journal:  J Pers Med       Date:  2022-07-29

Review 4.  Building a Personalized Medicine Infrastructure for Gynecological Oncology Patients in a High-Volume Hospital.

Authors:  Nicolò Bizzarri; Camilla Nero; Francesca Sillano; Francesca Ciccarone; Marika D'Oria; Alfredo Cesario; Simona Maria Fragomeni; Antonia Carla Testa; Francesco Fanfani; Gabriella Ferrandina; Domenica Lorusso; Anna Fagotti; Giovanni Scambia
Journal:  J Pers Med       Date:  2021-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.